CIPLA.NS : Summary for CIPLA INR2 - Yahoo Finance

U.S. Markets closed

Cipla Limited (CIPLA.NS)

NSE - NSE Delayed Price. Currency in INR
Add to watchlist
571.20+3.00 (+0.53%)
At close: 4:59 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close568.20
Bid0.00 x
Ask571.20 x
Day's Range566.00 - 573.90
52 Week Range457.45 - 660.00
Avg. Volume1,382,183
Market Cap459.4B
PE Ratio (TTM)45.69
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters8 months ago

    Indian court extends relief to pharma firms in drug ban case

    Several companies, including Indian units of Abbott Laboratories and Pfizer Inc , and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted. On Monday, judge Rajiv Sahai Endlaw moved the hearing into his chamber from a courtroom packed with lawyers and company executives. Archana Sachdeva, a lawyer representing Cipla among other firms, said he had ordered the next hearing on March 28.

  • Reuters9 months ago

    US and EU regulators urge Indian drug companies to step up standards

    U.S. and EU drug regulators called upon India's pharmaceutical sector on Tuesday to step up efforts to improve manufacturing standards and ensure the reliability of data if it is to maintain its dominance in the generic drugs industry. India's $15 billion pharmaceutical industry, an increasingly important global supplier of cheaper generic medicines, has been dogged by concerns over quality issues after the U.S. Food and Drug Administration banned a series of factories from producing medicines for the United States due to inadequate standards. The European Medicines Agency (EMA), and the UK's Medicines and Health Regulatory Authority (MHRA) also barred some Indian plants from producing drugs for their markets.

  • Reuterslast year

    India's Cipla to buy Hetero Drugs' US business for about $550 mln - report

    Indian generic drugmaker Cipla Ltd is set to buy the U.S. business of privately held rival Hetero Drugs for about $550 million, the Economic Times newspaper reported on Friday, citing people close to the ...